Prismic Pharmaceuticals is a specialty pharmaceutical company focused on the development of innovative prescription drugs with unique safety profiles to address pain and inflammation.
The company’s first prescription product candidate, PP101, (“micro-PEA”, being micronized palmitoylethanolamide with particle sizes of 0.6-10 micron), is in development for patients suffering from fibromyalgia as an adjunctive therapy to the current standard of care, specifically for those patients who are not achieving a satisfactory level of pain relief.
The company has acquired the worldwide licensing rights (with
the exception of Italy and Spain) to a proprietary form of palmitoylethanolamide from which PP101 has been formulated. Prismic has data indicating that when PP101 is administered concomitantly with treatments for severe chronic pain, such as pregabalin, duloxetine, or gabapentin or with narcotic analgesics/opiates, such as morphine, oxycodone, and hydrocodone, PP101 has a “potentiating” or “synergistic” effect on the other drug. As a result, the desired therapeutic effect can be achieved using a lower dose of the opiate or the effectiveness of other pain treatments such as pregabalin, duloxetine, or gabapentin, can be enhanced.
PP101 is protected by an extensive portfolio of issued and pending US and international patents The patent portfolio covers micro-PEA, alone and in combination with other molecules, including, but not limited to, opioids, across a broad array of medical conditions.
© Copyright by Prismic Pharmaceuticals, Inc.®, 2011-2019. All rights reserved.
Prismic Pharmaceuticals, Inc.
Attn: Zachary Dutton
474 Grove Street, Suite 740
Worcester, Massachusetts 01605